Active component

Active Component is a pharmaceutical company that specializes in the development and production of active pharmaceutical substances (APIs) using the latest technologies and equipment.

History

2025: Launch of production of pharmaceutical substances for the fight against cancer for 3.8 billion rubles in St. Petersburg

In December 2025, Active Component commissioned the first stage of production of highly active pharmaceutical substances (APIs) for antitumor drugs in St. Petersburg. The volume of investments in the project is 3.8 billion rubles.

According to RBC Petersburg, the production complex includes several specialized buildings. The first building is already functioning, the commissioning of the second is scheduled for the spring of 2026.

𝓲

Фото: Freepik

The manufactured substances are intended for drugs corresponding to 35 international non-proprietary names and included in the list of vital and essential drugs (VED). The products are used for the manufacture of drugs against cancer, as well as medicines for transplantology, the treatment of cardiovascular diseases and type II diabetes.

President of the "Active Component" Alexander Semenov said that in Russia there are practically no production of pharmaceutical substances for oncological drugs. In addition to this project, only one similar announced production is known - from JSC Biochemist of the Promomed group. After the complete launch of the complex, the company expects to occupy from 30 to 70% of the market for each of the manufactured substances.

The creation of production was announced at the St. Petersburg International Economic Forum in 2024. The project includes the construction of laboratory and production buildings for the production of cytostatics (antitumor agents), the expansion of its own R&D center (Research and Development - research and development center) and reconstruction with an increase in capacity by 50% of the main production in the city of Pushkin.

According to RBC Petersburg, Active Component supplies substances to 90% of domestic pharmaceutical companies, as well as to manufacturers in Belarus, Kazakhstan, Uzbekistan, Mongolia, Serbia and other countries. The company's portfolio includes over 80 substances, another 45 are in development. The total capacity of the two production sites in St. Petersburg is 400 tons per year.^[1]

2023: Protek acquired 44.7% of Active Component

On May 16, 2023, it became known that the Protek group of companies, the main owner of which is Russian businessman Vadim Yakunin, acquired a share of 44.7% in the manufacturer of Active Ingredient pharmaceutical substances.

It is noted that in March 2023, Anvilab LLC, as part of Protek, became the owner of a 19.6 percent stake in Vega LLC, the parent company of Active Component. As part of the new deal, the amount of which is not reported, the share was brought to 44.7%. Another 41% in Vega retained the Active Component, and the remaining part was divided by the founders of this enterprise - Alexander Semenov (7.9%) and Zievuddin Khodzhaev (6.4%).

Protek acquired a 44.7% stake in the manufacturer of Active Ingredient pharmaceutical substances

As stated on the Active Component website, the company joins forces with leading Russian and foreign pharmaceutical companies in order to "provide people with locally produced drugs in various fields of medicine." These are cardiological and antiviral agents, as well as antibiotics. As part of a partnership with Protec, seven new projects will be launched with a total investment of about 2.7 billion rubles. One of them provides for the construction of a plant for the production of intermediates.

The emergence of a new enterprise will help Active Component to fill the shortage of certain raw materials, the supply of which was reduced due to the current geopolitical situation. Cooperation with Protec will also improve performance against the background of falling sales of some antiviral drugs, in particular, funds to combat COVID-19.

We entered this year in partnership with the Protek group of companies and are very pleased with the development of our relationship. Accordingly, we will move towards the added value of selling full-cycle positions. Because, in my opinion, this is exactly the global strategic prospect of increasing profitability, "Semenov said.[2]

Notes